Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Reviva Pharmaceuticals Holdings Inc. stock (RVPH) is currently trading at $0.83. Analyst consensus price target for RVPH is $95.00. WallStSmart rates RVPH as Sell.
- RVPH PE ratio analysis and historical PE chart
- RVPH PS ratio (Price-to-Sales) history and trend
- RVPH intrinsic value — DCF, Graham Number, EPV models
- RVPH stock price prediction 2025 2026 2027 2028 2029 2030
- RVPH fair value vs current price
- RVPH insider transactions and insider buying
- Is RVPH undervalued or overvalued?
- Reviva Pharmaceuticals Holdings Inc. financial analysis — revenue, earnings, cash flow
- RVPH Piotroski F-Score and Altman Z-Score
- RVPH analyst price target and Smart Rating
Reviva Pharmaceuticals Holdings Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Reviva Pharmaceuticals Holdings Inc. (RVPH) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Reviva Pharmaceuticals Holdings Inc. (RVPH) Key Strengths (1)
Trading at 1.03x book value, attractively priced
Supporting Valuation Data
Reviva Pharmaceuticals Holdings Inc. (RVPH) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 4.49%
Micro-cap company with very limited liquidity and high volatility
Reviva Pharmaceuticals Holdings Inc. (RVPH) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.03) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -916.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -916.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RVPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Reviva Pharmaceuticals Holdings Inc. (RVPH) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Reviva Pharmaceuticals Holdings Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Reviva Pharmaceuticals Holdings Inc..
Bottom Line
Reviva Pharmaceuticals Holdings Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Reviva Pharmaceuticals Holdings Inc.(RVPH)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical firm focused on developing innovative therapies to address central nervous system (CNS) disorders and other significant health challenges. Its lead candidate, RP5063, offers a novel therapeutic approach for treating schizophrenia and mood disorders, underscored by a proprietary drug delivery platform designed to enhance treatment efficacy. With a robust pipeline and a commitment to meeting critical unmet medical needs, Reviva is strategically positioned for growth in the evolving mental health market as it advances through key clinical development milestones.